HT-08  Hot Topics 08
May 24 (Fri) 8:00 ~ 9:30  Room 3 (Osaka International Convention Center 10F Conference Room 1003)

Treatable cerebellar ataxias
Chairs: Kinya Ishikawa
The Center for Personalized Medicine for Healthy Aging
Yoshio Ikeda
Department of Neurology, Gunma University Graduate School of Medicine

HT-08-1  Ataxic form of autosomal recessive PEX10-related peroxisomal biogenesis disorders
Toru Yamashita
Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
HT-08-2  Anti-GAD antibody positive cerebellar ataxia
Kazunori Nanri
Sassa General Hospital

HT-08-3  Cerebellar ataxic form of Hashimoto's encephalopathy
Makoto Yoneda
Faculty of Nursing & Social Welfare Sciences, Fukui Prefectural University

HT-08-4  Paraneoplastic cerebellar ataxia
Keiko Tanaka
Department of Animal Model Development, Brain Research Institute, Niigata University / Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, School of Medicine

HT-08-5  Metabolic and drug-induced ataxia
Yoshio Ikeda
Department of Neurology, Gunma University Graduate School of Medicine

HT-09  Hot Topics 09
May 24 (Fri) 13:45 ~ 15:45  Room 10 (Osaka International Convention Center 12F Grande Toque)

Critical care in epilepsy
Chairs: Akio Ikeda
Department of Epilepsy, Movement Disorders and Physiology, Kyoto University Graduate School of Medicine, Japan
Masako Kinoshita
Department of Neurology, Utano National Hospital, National Hospital Organization, Japan

HT-09-1  Nonconvulsive seizures and status epilepticus in the critically ill: the silent epidemic
Lawrence J. Hirsch
Professor of Neurology and Chief of Epilepsy/EEG at Yale University, USA

HT-09-2  Seizures in the emergency department: benefits and limitations of clinical guidelines
Kazuhiro Kato
Japanese Red Cross Ishinomaki Hospital, Japan

HT-09-3  New Onset Refractory Status Epilepticus (NORSE): Diagnosis and Treatment
Yuto Uchida
Department of Neurology, Nagoya City University Graduate School of Medical Sciences, Japan / Department of Neurology, Toyokawa City Hospital, Japan

HT-09-4  Sudden unexpected death in epilepsy (SUDEP)
Kazutaka Jin
Department of Epileptology, Tohoku University Graduate School of Medicine, Japan

HT-09-5  Handling psychogenic nonepileptic seizures emergency cases
Go Taniguchi
Department of Neuropsychiatry, The University of Tokyo Hospital, Japan
G-02  New Guideline 02
May 24 (Fri) 8:00 ~ 9:30  Room 1 (Osaka International Convention Center 5F Large Hall)

Guideline for Parkinson disease
Chairs: Nobutaka Hattori
Department of Neurology, Juntendo University
Hirohisa Watanabe
Department of Neurology & Neuroscience, Fujita Health University

G-02-1  New Clinical Diagnostic Criteria for Parkinson's Disease
Satoshi Orimo
Department of Neurology, Kanto Central Hospital

G-02-2  Treatment of early Parkinson Disease
Atsushi Takeda
Department of Neurology, Sendai-Nishitaga Hospital

G-02-3  Treatment of Advanced Parkinson's disease
Yasushi Shimo
Department of Neurology, Juntendo University School of Medicine

S-20  Symposium 20
Proposed symposium
May 24 (Fri) 8:00 ~ 9:30  Room 5 (Osaka International Convention Center 10F Conference Room 1005-1007)

Diagnosis and Treatment of Duropathies
Chairs: Takemori Yamawaki
Hiroshima City Hiroshima Citizens Hospital
Keita Sakurai
Department of Radiology, Teikyo University School of Medicine

S-20-1  The concept and imaging findings of duropathies
Akira Yagishita
Tokyo Metropolitan Neurological Hospital, Dept. Neuroradiology

S-20-2  The diagnosis and treatment of CSF leak
Takashi Mitsufuji
Department of neurology, School of Medicine, Saitama Medical University

S-20-3  Diagnosis and Treatment of Superficial Siderosis
Takemori Yamawaki
Hiroshima City Hiroshima Citizens Hospital

S-20-4  Dose Hirayama disease have a duropathic nature?
Toshio Fukutake
Department of Neurology Kameda Medical Center

Nominal support: The Japanese Society of Neuroradiology
S-21 Symposium 21
May 24 (Fri) 8:00 ~ 9:30 Room 9 (Osaka International Convention Center 12F Conference Hall)

A compass for deciphering the pathophysiology of migraine

Chairs: Takao Takeshima  
Tominaga Hospital, Headache Center, Department of Neurology  
Toshihiko Shimizu  
EBARA CORPORATION

S-21-1 The clarification of migraine pathophysiology  
-the compass from in vivo study  
Eiichiro Nagata  
Department of Neurology, Tokai University School of Medicine

S-21-2 Insight into migraine pathophysiology gained from in vitro studies  
Mamoru Shibata  
Department of Neurology, Keio University School of Medicine

S-21-3 Compass for breakthrough of pathophysiology in migraine from neurophysiological studies  
Koichi Shibata  
Department of Medicine (Neurology), Tokyo Women's Medical University Medical Center East

S-21-4 Physiopathology of Migraine: What have we learned from functional imaging?  
Noboru Imai  
Department of Neurology, Japanese Red Cross Shizuoka Hospital

Nominal support: The Japanese headache society

S-22 Symposium 22
May 24 (Fri) 8:00 ~ 9:30 Room 10 (Osaka International Convention Center 12F Grande Toque)

Crosstalk between brain and liver

Chairs: Hiroaki Miyajima  
First Department of Medicine, Hamamatsu University School of Medicine  
Yoshiki Sekijima  
Department of Medicine (Neurology & Rheumatology), Shinshu University School of Medicine

S-22-1 Precise diagnosis of Wilson disease  
Akihiro Matsuura  
Fujita Health University School of Medicine

S-22-2 Pathomechanism and development of effective therapies for adult-onset citrullinemia (CTLN2)  
Masahide Yazaki  
Institute for Biomedical Sciences, Shinshu University / Shinshu University School of Health Sciences
Cerebrotendinous xanthomatosis: molecular pathogenesis and disease-modifying treatments
Shingo Koyama
Department of Internal Medicine III, Yamagata University School of Medicine

hereditary ATTR cerebral amyloid antipathy and liver transplantation
Taro Yamashita
Department of Neurology, Graduate School of Medical Sciences, Kumamoto University / Organization Project of Practice System for Neurological Intractable Disease, Kumamoto University Hospital

S-23 Symposium 23

May 24 (Fri) 8:00 ~ 9:30 Room 11 (Osaka International Convention Center 12F Conference Room 1202)

What is the first thing that the neurologist do when there is a disaster?

Chairs: Kouichi Mizoguchi
Shizuoka Medical Center
Osamu Yamamura
Department of Neurology, University of Fukui Hospital

DMAT activity in the disaster medicine
Yuichi Koido
National Hospital Organization Disaster Medical Center

Activity of Perinatal and Pediatric Disaster Medical Liaison
Miho Misaki
National Disaster Medical Center

Practice of Disaster Medicine: Patient image of a neurological disease encountered at a shelter
Osamu Yamamura
Department of Neurology, University of Fukui Hospital

Individual evacuation support plan at disaster for patients with intractable diseases
Chizu Wada
Akita national hospital

Disaster Response of Japanese Society of Neurology
Kouichi Mizoguchi
Shizuoka Medical Center
S-24 Symposium 24
May 24 (Fri) 13:45 ~ 15:45  Room 1 (Osaka International Convention Center 5F Large Hall)

Potential disease modifying therapies for Parkinson disease

Chairs: Atsushi Takeda  
National Hospital Organization, Sendai-Nishitaga Hospital, Japan  
Kenya Nishioka  
Juntendo University School of Medicine, Japan

S-24-1 Therapies for PD via modifying actions of extracellular alpha-synuclein  
Seung-Jae Lee  
Department of Biomedical Sciences, Seoul National University College of Medicine, Korea

S-24-2 Challenges in trials of disease modifying therapies in Parkinson disease  
Camille Carroll  
University of Plymouth Faculty of Medicine and Dentistry, UK / University Hospitals Plymouth NHS Trust, UK

S-24-3 In silico drug screening by using GWAS-data for Parkinson’s disease  
Tatsushi Toda  
Department of Neurology, Graduate School of Medicine, The University of Tokyo, Japan

S-24-4 Cholinesterase inhibitor may improve PD prognosis  
Toru Baba  
Department of Neurology, Sendai-Nishitaga National Hospital, Japan

S-25 Symposium 25
May 24 (Fri) 13:45 ~ 15:45  Room 4 (Osaka International Convention Center 10F Conference Room 1001-1002)

New drug development and the change of treatment strategy in MG

Chairs: Tomihiro Imai  
Sapporo Medical University School of Health Sciences, Japan  
Hiroyuki Murai  
International University of Health and Welfare, Japan

S-25-1 Overview:  
Why is the development of new treatment necessary in MG area?  
Tomihiro Imai  
Sapporo Medical University School of Health Sciences, Japan

S-25-2 New Drug Development for Myasthenia Gravis  
Henry J. Kaminski  
George Washington University, USA

S-25-3 Challenges and developments in MG care in Europe  
Maria I Leite  
University of Oxford, UK / Oxford University Hospitals NHS Foundation Trust, UK
S-25-4  The innovative treatment strategy for patients with myasthenia gravis in Taiwan
Hou-Chang Chiu
Fu-Jen Catholic University Hospital, Taiwan / Shin Kong WHS Memorial Hospital, Taiwan / College of Medicine, Fu-Jen Catholic University, Taiwan

S-25-5  A possible new treatment for MG: Fc fusion protein, AChR-Fc
Akiyuki Uzawa
Department of Neurology, Graduate School of Medicine, Chiba University, Japan

S-26 Symposium 26
May 24 (Fri) 13:45 ~ 15:45 Room 5 (Osaka International Convention Center 10F Conference Room 1005-1007)

Pregnancy planning and outcome in neuroimmunological disorders
Chairs: Izumi Kawachi
Dept. of Neurology, Brain Research Institute, Niigata University
Kazuo Fujihara
Fukushima Medical University

S-26-1  Pregnancy in women with multiple sclerosis and neuromyelitis optica
Yuko Shimizu
Department of Neurology, Tokyo Women’s Medical University

S-26-2  Pregnancy and birth on the course of myasthenia gravis
Shigeaki Suzuki
Keio University School of Medicine, Department of Neurology

S-26-3  Pregnancy of patients with rheumatic diseases accompanying neurological symptoms
Atsuko Murashima
National Center for Child Health and Development, Division of Maternal Medicine, Japan Drug Information Institute in Pregnancy

S-26-4  A review of infertility treatment: Assisted Reproductive Technology for immune neurological diseases
Keiichi Kato
Kato Ladies Clinic
Current topics in Guillain-Barré syndrome
- from pathophysiology to clinical features

Chairs: Kenichi Kaida
Division of Neurology, Department of Internal Medicine, National Defense Medical College, Japan
Atsuro Chiba
Department of Neurology, School of Medicine, Kyorin University, Japan

- S-27-1 Recent advances of anti-glycolipid antibody research in GBS
  Hugh Willison
  University of Glasgow, Scotland

- S-27-2 Ca2+-dependent anti-GQ1b antibody:
  From a new assay method to an insight for paranodal gangliosides
  Atsuro Chiba
  Department of Neurology, Faculty of Medicine, Kyorin University, Japan

- S-27-3 New observations from the International GBS Outcome Study (IGOS)
  Bart Jacobs
  Departments of Neurology and Immunology, Erasmus University Medical Center, The Netherlands

- S-27-4 Nodopathy:
  The third electrophysiologic category in Guillain-Barré syndrome
  Satoshi Kuwabara
  Department of Neurology, Graduate School of Medicine, Chiba University, Japan

- S-27-5 Guillain-Barré syndrome in Japan; clinical features and prediction of prognosis
  Yuko Yamagishi
  Department of Neurology, Kindai University, Faculty of Medicine, Japan

New concepts of glia and brain homeostasis:
key missing pieces in the puzzle of neurological disorders

Chairs: Koji Yamanaka
Research Institute of Environmental Medicine, Nagoya University, Japan
Makoto Higuchi
National Institutes for Quantum and Radiological Science and Technology, Japan

- S-28-1 Overview: glia as therapeutic targets for neurodegenerative diseases
  Koji Yamanaka
  Research Institute of Environmental Medicine, Nagoya University, Japan
S-28-2  Regulatory T cell modulation of neuroinflammation and progression in amyotrophic lateral sclerosis
Bradley Turner
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Australia

S-28-3  Reactive Astrocytes, MAO-B, GABA, Hydrogen Peroxide, and Alzheimer’s Disease
C. Justin Lee
Institute for Basic Science, Korea

S-28-4  Novel function of lipid mediators for the microglial fate determination of injured neurons
Hiroshi Kiyama
Dept. of Functional anatomy & Neuroscience, Grad. Sch. Med., Nagoya University, Japan

S-28-5  Novel homeostatic function of glial cells in health and disease
Makoto Higuchi
National Institutes for Quantum and Radiological Science and Technology, Japan

S-29  Symposium 29

May 24 (Fri) 13:45 ~ 15:45  Room 9 (Osaka International Convention Center 12F Conference Hall)

Drug development by open innovation with pharmaceutical company

Chairs: Takanori Yokota
Tokyo Medical and Dental University
Sonoko Misawa
Chiba University Graduate School of Medicine

S-29-1  Industry Academia Alliance
Kaori Iida
Professor Director Institute of Research Division for Research Innovation Research Center for Industry Alliances / Acting Director Institute of Open Innovation Tokyo Medical and Dental University (TMDU)

S-29-2  Expectation to academia with accelerated diversification of pharmaceutical modality
Yasushi Kajii
Neuroscience Medical Franchise Department, Medical Division, Novartis Pharma K.K.

S-29-3  Roles of life sciences startup companies in medical innovation
Koichi Ashida
INCJ, Ltd.

S-29-4  Support of drug development by academic-industrial collaboration
Haruhiko Hakuno
Director, Research and Development Division, Health Policy Bureau, Ministry of Health, Labour and Welfare

S-29-5  Global trend of drug development for CNS diseases
Keiji Yamamoto
Innovative Biology Labs., Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Ltd.
To the ocean of Brain visualization research

**Chairs:** Hirohisa Watanabe  
Department of Neurology & Neuroscience, Fujita Health University  
Hitoshi Shimada  
Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology

---

**S-30-1**  
Recent advances of 7T ultra high field MRI in neuroimaging research  
Masaki Fukunaga  
Division of Cerebral Integration, National Institute for Physiological Sciences / School of Life Science, The Graduate University for Advanced Studies (SOKENDAI)

---

**S-30-2**  
A network-based analysis for higher brain function  
Wataru Sako  
Department of Clinical Neuroscience, Tokushima University Graduate School

---

**S-30-3**  
Next generation PET studies toward developing disease modifying therapies  
Hitoshi Shimada  
Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology

---

**S-30-4**  
EIRL: The medical image diagnostic technology with AI  
Yoshiki Soeda  
LPixel Inc.

---

**S-30-5**  
Usefulness of diffusion MRI for MRI-negative neurological disorders  
Yukio Kimura  
National Center of Neurology and Psychiatry Hospital, Department of Radiology

---

**SS-05**  
Special Session 05

**May 24 (Fri) 8:00 ~ 9:30  Room 4 (Osaka International Convention Center 10F Conference Room 1001-1002)**

Let's start the basic research even after the clinical training by the presidents of scientific societies

**Chairs:** Tatsushi Toda  
Department of Neurology, Graduate School of Medicine, The University of Tokyo  
Hideki Mochizuki  
Department of Neurology, Osaka University

---

**SS-05-1**  
The attraction of basic research  
Tatsushi Toda  
Department of Neurology, Graduate School of Medicine, The University of Tokyo
Welcome to basic sciences, a message from the President of the Japan Neuroscience Society
Tadashi Isa
Graduate School of Medicine, Kyoto University / Institute for the Advanced Study of Human Biology, Kyoto University / Human Brain Science Center, Kyoto University

Wonderful world created by the research in neurochemistry
Keiji Wada
National Institute of Neuroscience, National Center of Neurology and Psychiatry

Nominal support: The Japanese Society for Neurochemistry, The Japan Neuroscience Society

Late Breaking Symposium
May 24 (Fri) 14:45 ~ 15:45 Room 12 (Osaka International Convention Center 11F Conference Room 1101-1102)
Chair: Kazumasa Saigoh
Kindai University, Department of Clinical Genetics
Commentator: Yoshiyuki Mitsui
Kindai University Faculty of Medicine Center for General Medical Education and Clinical Training

*NSee the web site for the further information.

Neuroscience Frontier Symposium 02
May 25 (Sat) 8:00 ~ 10:00 Room 3 (Osaka International Convention Center 10F Conference Room 1003)
The emergence of a new era of gene therapy and regenerative medicine in Neurology
Chairs: Hitoshi Okazawa
Tokyo Medical and Dental University, Japan
Haruhisa Inoue
Dept. of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Japan

Gene therapy with therapeutic oligonucleotide
Tetsuya Nagata
Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan

Block of neuraxial degeneration by silencing an ALS-causing mutant gene with subpial AAV9 delivery
Martin Marsala
University of California, San Diego, USA

Gene therapy for Parkinson's disease
Shin-ichi Muramatsu
Division of Neurology, Department of Medicine, Jichi Medical University, Japan / Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Japan / Department of Neurology, Osaka University Graduate School of Medicine, Japan